This activity is supported by educational grants from AstraZeneca, Clovis Oncology, Lilly, and Merck & Co.
Management of Patients Treated With Immunotherapy
Beth Eaby-Sandy, MSN, CRNP, OCN®
University of Pennsylvania
Immunotherapy, one of the most important breakthroughs for cancer treatment in the past decade, is demonstrating its effectiveness across tumor types, including non–small cell lung cancer. This activity will provide information on the newest agents in the armamentarium for treating non–small cell lung cancer, including PD-1 inhibitor, and anti-CTLA4 immunotherapy. In addition, the discussion will include the recognition and management of potential immune-mediated adverse events unique to immune checkpoint inhibitors.
Use of Diagnostic Tests in Advanced Non–Small Cell Lung Cancer: Skills Presentation
Management of Patients With Cytotoxic Chemotherapy
Targeted Therapies in Advanced Non–Small Cell Lung Cancer
Navigating the Landscape of Molecular Testing and Treatments With Targeted Therapies for Patients With Non-Small Cell Lung Cancer
What is the role of EGFR mutations in patients with NSCLC?
What is T790m and describe its role in drug resistance?
What is ALK and how does it impact the treatment of NSCLC?
What should advanced practitioners know about the side effect profiles of targeted treatments for NSCLC?
What should pharmacists know about combining treatment agents for patients with NSCLC?
Bone Marrow Biopsy Demonstration Video